|
|
| | ARS-1630 Basic information |
| Product Name: | ARS-1630 | | Synonyms: | ARS-1630;CPD2016;ARS-1630;ARS 1630;ARS1630;(R)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one;2-Propen-1-one, 1-[4-[(7R)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-quinazolinyl]-1-piperazinyl]-;inhibit,Ras,ARS-1630,ARS1630,Inhibitor,ARS 1630 | | CAS: | 1698055-86-5 | | MF: | C21H17ClF2N4O2 | | MW: | 430.84 | | EINECS: | | | Product Categories: | | | Mol File: | 1698055-86-5.mol |  |
| | ARS-1630 Chemical Properties |
| Boiling point | 614.7±55.0 °C(Predicted) | | density | 1.434±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 69 mg/mL (160.15 mM) | | pka | 6.03±0.35(Predicted) |
| | ARS-1630 Usage And Synthesis |
| Definition | ChEBI: ARS-1620 is a qinazoline derivative carrying chloro and fluoro substituents at positions 6 and 8 respectively, a 2-fluoro-6-hydroxyphenyl group at position 7, and a 4-(prop-2-enoyl)piperazin-1-yl group at position 4. A potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor, it inhibits the protein coding gene KRAS (Kirsten rat sarcoma virus) with high potency in cells and animals. It has a role as an inhibitor, an antiviral agent and an antineoplastic agent. |
| | ARS-1630 Preparation Products And Raw materials |
|